• Data from CheckMate 066 are relatively immature. The available EQ-5D observations are concentrated in the first 6 months of study follow-up.
• The residual treatment effect observed for the treatment arm parameter in Model 3 for both trials is assumed to be attributable to different adverse event (AEs) profiles across treatment arms. It was not possible to incorporate specific AEs into the longitudinal models due to the relatively low number of AEs within each type of event and the need to have a proximal and preceding EQ-5D assessment.
• In CheckMate 066, comparing nivolumab vs. DTIC, the EQ-5D was administered during each 6-week cycle, with initial assessments taken at randomization. During the follow-up (off-treatment) phase, EQ-5D assessments continued to be taken every three months for the next 12 months.
• EQ-5D responses were used to generate index utility scores using the UK time trade off (TTO) method 1
• The SAS PROC MIXED was used to estimate longitudinal mixed linear models of utility over time. This mixed linear model has a random intercept for each patient and an unstructured covariance specification.
• Akaike Information Criteria (AIC), as well as statistical significance, qualitative assessment/clinical plausibility, and relevance to the economic modeling efforts were considered when comparing models and parameters. Three models were selected for the final analysis and are presented here.
• 
Objective:
The aim was to assess predictors of health-related quality of life over time to estimate utilities for patients with treatment-naïve advanced melanoma in the randomized CheckMate 066 trial comparing nivolumab versus dacarbazine (DTIC) for use in a cost-effectiveness model (CEM).
Methods:
The EQ-5D was administered at baseline and every 6 weeks in CheckMate 066 and was used to generate index utility scores using the UK time trade off (TTO) method. Covariates were based on a combination of prior analyses of large trial datasets, including patient demographic and clinical characteristics, quantitative metrics of fit, qualitative/clinical plausibility, and relevance to the CEM. Several longitudinal mixed linear models were explored using different covariate sets.
Results: This analysis included 288 patients and 1,125 visits where the EQ-5D was administered. Mean baseline utility score was 0.75 for nivolumab patients, 0.69 for dacarbazine, and 0.72 across all patients. The final model included baseline utility (to adjust for imbalance between treatment arms), progression status (pre/post), days until death or end of follow-up (<30 days/30+ days), and treatment arm. Parameter estimates in the model were 0.603 for baseline utility (p<0.001), -0.074 for progression status (p<0.001), -0.022 for <30 days left (P=0.092), and -0.069 for treatment arm (DTIC vs. nivolumab) (p=0.008). When implemented in the CEM, the utility estimate for the pre-progression and post-progression states were 0.802 and 0.728, respectively (applying nivolumab as the treatment arm). A decrement for the month preceding death is applied using the estimate for <30 days until death or end of followup (-0.022).
Conclusions:
Results showed that baseline utility, progression, <30 days until death or end of follow-up, and treatment arm are predictors of utility over time, which is consistent with prior work in melanoma. As data mature, these analyses will be replicated in this and other nivolumab trials.
• Survival, progression, and health-related quality of life (HRQoL) are the central outcome measures in health technology assessment of oncology treatments.
• Health states used in economic evaluations in oncology typically center on progression status with the key measure of effectiveness being quality-adjusted survival.
• A cost-effectiveness model (CEM) comparing nivolumab, an anti-PD-1 agent used to treat advanced melanoma, to competing treatments, including DTIC, has been developed.
• The CEM includes three health states: pre-progression, post-progression, and death, and employs a partitioned survival analysis approach in which progression and survival are modeled separately. Survival extrapolations in the CEM are stratified by response status at 6-months (landmark), one of the key endpoints in the nivolumab clinical trials.
• The CEM evaluates the implications of treatments with nivolumab over a long time horizon, so it is important to understand how utility changes over time. • There were fewer observations per patient in the DTIC arm than in the nivolumab arm in CheckMate 066. (Table 1) • This is likely due to the faster rate of progression among DTIC patients as reported in the trial (median progression free survival of 2.2 months for DTIC vs. 5.1 for nivolumab) 2 .
• While there are EQ-5D assessments for approximately one full year of follow-up, the vast majority of assessments occurred in the first six months.
• There was an imbalance between the nivolumab and DTIC arms in the visit 1 utility estimates from the CheckMate 066 trial. Nivolumab patients had a higher utility at visit 1 than DTIC patients (0.75 vs. 0.69) ( Table 2 ) Table 1 . Number of visits where an EQ-5D was administered *excluding patients with missing study treatment. Table 2 . Mean EQ-5D at Visit 1
• Table 3 presents Model 1 which explores the potential for time to death to influence utility alongside other important variables, including adjusting for the imbalance in visit 1 EQ-5D.
• Only the most proximal period to death (29 days or less) was associated with a significant decrease in HRQoL utility (p<0.05); the post progression state and visit 1 EQ-5D are very highly significant (both p<0.0001). • Table 4 shows that including response status at landmark (LM), combined with the time-varying progression status in Model 2 does not improve the precision of the model.
• Further, the inclusion of the landmark response/progression status variable reduces the sample size substantially from 1020 to 334 observations due to the number of patients who are censored before the landmark point. Table 5) • Model 3 is highly predictive and includes both a time-varying progression variable and an indicator for having 29 days or less left.
• The treatment indicator remains significant in the model even after adjusting for baseline imbalance.
• Model 3 was therefore selected for implementation of utility estimates in the CEM.
• When implemented in the CEM, the utility estimate for the pre-progression and post-progression states were 0.802 and 0.728, respectively (applying nivolumab as the treatment arm). A decrement for the month preceding death is applied using the estimate for <30 days until death or end of followup (-0.022). 
Conclusions
• This analysis showed that baseline utility, progression status, and time to death were significant predictors of utility over time, which is consistent with prior analyses in advanced melanoma.3
• Due to the preliminary nature of the available data at this time, these analyses should be revisited as data mature.
